CV Technologies-Maker of Cold-FX(R)-Named in the '2005 TSX Venture 50'

TORONTO, CANADA--(CCNMatthews - Dec. 6, 2005) - CV Technologies Inc. (TSX
VENTURE:CVQ) (CVT) was today named the top ranked company in the 2005 TSX
Venture 50(TM), the first ever ranking of Canada's top emerging public
companies listed on the TSX Venture Exchange.

The TSX Venture 50 is a list of the top 10 companies in each of five major
industry sectors - life sciences, mining, oil & gas, technology and diversified
industries - based on a ranking formula with equal weighting given to one-year
revenue (last reported 12 months), return on investment, market cap growth and
trading volume. All data was as of August 31, 2005. There are 1,983 companies
listed on the exchange.

The list is a joint venture with Profit magazine and is designed to showcase
the Exchange's leading companies and to increase investor awareness of the top
performing companies on the Exchange.

"We are very proud to launch the TSX Venture 50 to celebrate the achievements
of our issuers," said Linda Hohol, President, TSX Venture Exchange. "The
impressive list of companies demonstrates that the TSX Venture Exchange is a
unique incubator of public companies, and the companies in the TSX Venture 50
are living proof as to why this market is working."

Ms Hohol added, "We are proud to announce CV Technologies as the top company of
our first TSX Venture 50. Having a life sciences company at the top of the list
is very encouraging and demonstrates the diversity of the Exchange which has
its roots in the natural resource sector."

"Being named to the TSX Venture 50 is a great recognition of our
accomplishments as a company," said CVT president and CEO, Dr. Jacqueline Shan.
"To be selected as the number one company overall is a tribute to the hard work
of our employees and the successful execution of our business strategy. We are
grateful for the incredible support we've received from all our partners at the
retail and wholesale levels, as well as from all our loyal customers", she

CV Technologies' lead product, COLD-fX(R), is the number one selling cold and
flu remedy in Canada according to ACNielsen. Last week the Company posted net
profits of $10.1 million on revenue of $31.9 million for the fiscal year ending
Sept 30, 2005 compared to $151,000 profit and revenue of $6.4 million for the
previous year.

Over 98 million shares of CV Technologies were traded during the 12 month
ranking period. The share price increased from $0.65 on September 1, 2004 to
close at $3.25 August 31, 2005. The market capitalization increased 450% from
$59 million to $325 million during the same period.


CV Technologies, founded in 1992, is a global leader in the development and
commercialization of naturally derived, evidence based, clinically tested,
medicines for disease prevention and health maintenance. CVT's lead product -
COLD-fX(R), - the top selling cold and flu remedy in Canada according to
ACNielsen, strengthens the immune system and is widely used as a leading
anti-cold, anti-flu, non-prescription treatment. COLD-fX's unique, patented,
mechanism of action was developed and standardized according to the Company's
ChemBioPrint (CBP(R)) technology. The CBP(R) process precisely identifies the
chemical profile and biological activity of multi-active components in natural
compounds. The CBP(R) process provides a manufacturing protocol that ensures
each batch of compound delivers verifiable and provable health benefits.

The 2005 TSX Venture 50 (TM) was compiled based on public historical date and
is not an invitation to purchase securities listed on Toronto Stock Exchange
and/or TSX Venture Exchange.

TSX Group Inc. and its affiliates do nor endorse or recommend any securities
reference in this ranking. Neither TSX Group Inc. nor its affiliated companies
represent, warrant or guarantee the accuracy or the completeness of the
information. You should not rely on this information contained herein for any
trading, business or financial purposes. TSX Group Inc. and its affiliates
assume no liability for any errors or inaccuracies herein or any use or
reliance upon this information.

This news release contains forward-looking statements that involve risks and
uncertainties, which may cause actual results to differ materially from the
statements made. For this purpose, any statements that are contained herein
that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes",
"anticipates", "plans", "intends", "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to, the need for capital, changing market
conditions, completion of clinical trials, patient enrolment rates, uncertainty
of pre-clinical, retrospective and early clinical trial results, the
establishment of manufacturing processes and new corporate alliances, the
timely development, regulatory approval and market acceptance of the Company's
products, and other risks detailed from time to time in the Company's filings
with Canadian securities authorities.

- 30 -

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.